Filing Analysis
Securities Offering
Filed Apr 24, 2026
MEDIUM
Lucid Diagnostics Inc. closed a public offering of 18,000,000 shares of common stock at a price of $1.00 per share. The offering resulted in approximately $16.8 million in net proceeds intended for working capital and general corporate purposes.
Red Flags
- Significant shareholder dilution resulting from the issuance of 18 million new shares.
- The $1.00 price point may represent a discount to the market price depending on the trading history prior to the offering.
Key Facts
- Closed the sale of 18,000,000 shares of common stock on April 24, 2026.
- Offering price was set at $1.00 per share.
- Net proceeds are expected to be approximately $16.8 million after underwriting discounts and expenses.
- Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners.
- The offering was conducted under an existing shelf registration statement on Form S-3 (No. 333-291981).
Securities Offering
Filed Apr 23, 2026
HIGH
Lucid Diagnostics Inc. entered into an underwriting agreement for a public offering of 18,000,000 shares of common stock at a price of $1.00 per share. The offering is expected to generate gross proceeds of $18 million before expenses.
Red Flags
- Significant potential dilution to existing shareholders from the issuance of 18 million new shares.
- The $1.00 offering price suggests the company is operating in a low-share-price environment, which often precedes delisting risks or reverse splits in micro-cap stocks.
Key Facts
- Public offering price set at $1.00 per share.
- Total of 18,000,000 shares of common stock to be sold.
- Gross proceeds of $18,000,000; net proceeds of $0.94 per share after underwriting discounts.
- Underwriters include Canaccord Genuity LLC and BTIG, LLC.
- The offering is expected to close on or about April 24, 2026.
- Offering conducted under an existing shelf registration statement (Form S-3).
Regulation FD Disclosure
Filed Mar 26, 2026
LOW
Lucid Diagnostics Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a business update. The disclosure was made via a press release on March 26, 2026, and furnished under Items 2.02 and 7.01.
Key Facts
- Reported financial results for the fiscal year ended December 31, 2025
- Filing date: March 26, 2026
- Exhibit 99.1 contains the full press release and business update
- The report was signed by Dennis McGrath, Chief Financial Officer
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.